{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:19:26Z","timestamp":1771460366883,"version":"3.50.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,3,1]],"date-time":"2010-03-01T00:00:00Z","timestamp":1267401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.4158\/ep09155.ra","type":"journal-article","created":{"date-parts":[[2010,1,14]],"date-time":"2010-01-14T21:36:13Z","timestamp":1263504973000},"page":"324-333","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":64,"title":["Rationale for Leptin-Replacement Therapy for Severe Lipodystrophy"],"prefix":"10.1016","volume":"16","author":[{"given":"Elif A.","family":"Oral","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4158\/EP09155.RA_bb0010","doi-asserted-by":"crossref","unstructured":"Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract. 16:310-323.","DOI":"10.4158\/EP09154.RA"},{"key":"10.4158\/EP09155.RA_bb0015","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1136\/jcp.2007.049171","article-title":"Adipokines and the clinical laboratory: what to measure, when and how?","volume":"62","author":"Hill","year":"2009","journal-title":"J Clin Pathol"},{"key":"10.4158\/EP09155.RA_bb0020","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/372425a0","article-title":"Positional cloning of the mouse obese gene and its human homologue","volume":"372","author":"Zhang","year":"1994","journal-title":"Nature"},{"key":"10.4158\/EP09155.RA_bb0025","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1152\/ajplegacy.1969.217.5.1298","article-title":"Effects of parabiosis of normal with genetically diabetic mice","volume":"217","author":"Coleman","year":"1969","journal-title":"Am J Physiol"},{"key":"10.4158\/EP09155.RA_bb0030","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/BF01221857","article-title":"Effects of parabiosis of obese with diabetes and normal mice","volume":"9","author":"Coleman","year":"1973","journal-title":"Diabetologia"},{"key":"10.4158\/EP09155.RA_bb0035","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1126\/science.7624777","article-title":"Weight-reducing effects of the plasma protein encoded by the obese gene","volume":"269","author":"Halaas","year":"1995","journal-title":"Science"},{"key":"10.4158\/EP09155.RA_bb0040","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/0092-8674(95)90151-5","article-title":"Identification and expression cloning of a leptin receptor, OB-R","volume":"83","author":"Tartaglia","year":"1995","journal-title":"Cell"},{"key":"10.4158\/EP09155.RA_bb0045","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0092-8674(00)81294-5","article-title":"Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db\/db mice","volume":"84","author":"Chen","year":"1996","journal-title":"Cell"},{"key":"10.4158\/EP09155.RA_bb0050","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/379632a0","article-title":"Abnormal splicing of the leptin receptor in diabetic mice","volume":"379","author":"Lee","year":"1996","journal-title":"Nature"},{"key":"10.4158\/EP09155.RA_bb0055","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1056\/NEJM199909163411204","article-title":"Effects of recombinant leptin therapy in a child with congenital leptin deficiency","volume":"341","author":"Farooqi","year":"1999","journal-title":"N Engl J Med"},{"key":"10.4158\/EP09155.RA_bb0060","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1172\/JCI0215693","article-title":"Beneficial effects of leptin on obesity, T cell hyporesponsiveness, and neuroendocrine\/metabolic dysfunction of human congenital leptin deficiency","volume":"110","author":"Farooqi","year":"2002","journal-title":"J Clin Invest"},{"key":"10.4158\/EP09155.RA_bb0065","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/382250a0","article-title":"Role of leptin in the neuroendocrine response to fasting","volume":"382","author":"Ahima","year":"1996","journal-title":"Nature"},{"key":"10.4158\/EP09155.RA_bb0070","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1172\/JCI200317490","article-title":"The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men","volume":"111","author":"Chan","year":"2003","journal-title":"J Clin Invest"},{"key":"10.4158\/EP09155.RA_bb0075","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1210\/jcem.87.5.8624","article-title":"Serum adiponectin and leptin levels in patients with lipodystrophies","volume":"87","author":"Haque","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09155.RA_bb0080","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1530\/eje.0.1400107","article-title":"Extremely low values of serum leptin in children with congenital generalized lipoatrophy","volume":"140","author":"Jaquet","year":"1999","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP09155.RA_bb0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/43448","article-title":"Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy","volume":"401","author":"Shimomura","year":"1999","journal-title":"Nature"},{"key":"10.4158\/EP09155.RA_bb0090","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1038\/35002663","article-title":"Leptin and diabetes in lipoatrophic mice [with discussion]","volume":"403","author":"Gavrilova","year":"2000","journal-title":"Nature"},{"key":"10.4158\/EP09155.RA_bb0095","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/90984","article-title":"The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity","volume":"7","author":"Yamauchi","year":"2001","journal-title":"Nat Med"},{"key":"10.4158\/EP09155.RA_bb0100","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1056\/NEJMoa012437","article-title":"Leptin-replacement therapy for lipodystrophy","volume":"346","author":"Oral","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4158\/EP09155.RA_bb0105","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.2337\/diabetes.54.7.1994","article-title":"Long-term efficacy of leptin replacement in patients with generalized lipodystrophy","volume":"54","author":"Javor","year":"2005","journal-title":"Diabetes"},{"key":"10.4158\/EP09155.RA_bb0110","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.metabol.2006.11.010","article-title":"Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy","volume":"56","author":"Park","year":"2007","journal-title":"Metabolism"},{"key":"10.4158\/EP09155.RA_bb0115","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2265.2007.03095.x","article-title":"Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation","volume":"68","author":"Guettier","year":"2008","journal-title":"Clin Endocrinol (Oxf)"},{"key":"10.4158\/EP09155.RA_bb0120","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1210\/jc.2007-1856","article-title":"Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy","volume":"93","author":"Park","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09155.RA_bb0125","doi-asserted-by":"crossref","first-page":"2605","DOI":"10.1210\/jc.2005-1545","article-title":"Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy","volume":"91","author":"Lee","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09155.RA_bb0130","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1210\/jc.2008-1588","article-title":"The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia","volume":"94","author":"Mulligan","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09155.RA_bb0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00125-009-1502-9","article-title":"Efficacy of leptin therapy in the different forms of human lipodystrophy","volume":"53","author":"Chong","year":"2010","journal-title":"Diabetologia"},{"key":"10.4158\/EP09155.RA_bb0140","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1210\/jc.2006-1546","article-title":"Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy","volume":"92","author":"Ebihara","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09155.RA_bb0145","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1542\/peds.2006-3165","article-title":"Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy","volume":"120","author":"Beltrand","year":"2007","journal-title":"Pediatrics"},{"key":"10.4158\/EP09155.RA_bb0150","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.metabol.2003.10.019","article-title":"Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy","volume":"53","author":"Moran","year":"2004","journal-title":"Metabolism"},{"key":"10.4158\/EP09155.RA_bb0155","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1210\/jc.2003-031868","article-title":"Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency","volume":"89","author":"McDuffe","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09155.RA_bb0160","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.2337\/diabetes.50.6.1440","article-title":"Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes","volume":"50","author":"Ebihara","year":"2001","journal-title":"Diabetes"},{"key":"10.4158\/EP09155.RA_bb0165","doi-asserted-by":"crossref","first-page":"2328","DOI":"10.1210\/endo.141.7.7536","article-title":"In vivo administration of leptin activates signal transduction directly in insulin-sensitive tissues: overlapping but distinct pathways from insulin","volume":"141","author":"Kim","year":"2000","journal-title":"Endocrinology"},{"key":"10.4158\/EP09155.RA_bb0170","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1073\/pnas.96.5.2327","article-title":"Regulation of fatty acid homeostasis in cells: novel role of leptin","volume":"96","author":"Unger","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4158\/EP09155.RA_bb0175","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/415339a","article-title":"Leptin stimulates fatty-acid oxidation by activating AMP-activated protein kinase","volume":"415","author":"Minokoshi","year":"2002","journal-title":"Nature"},{"key":"10.4158\/EP09155.RA_bb0180","doi-asserted-by":"crossref","first-page":"11848","DOI":"10.1073\/pnas.182420899","article-title":"PPAR alpha is necessary for the lipopenic action of hyperleptinemia on white adipose and liver tissue","volume":"99","author":"Lee","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4158\/EP09155.RA_bb0185","first-page":"E1","article-title":"Malonyl-CoA, fuel sensing, and insulin resistance","volume":"276","author":"Ruderman","year":"1999","journal-title":"Am J Physiol"},{"key":"10.4158\/EP09155.RA_bb0190","doi-asserted-by":"crossref","first-page":"863","DOI":"10.2337\/diab.44.8.863","article-title":"Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications","volume":"44","author":"Unger","year":"1995","journal-title":"Diabetes"},{"key":"10.4158\/EP09155.RA_bb0195","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2174\/0929867043455620","article-title":"Nutrient-induced insulin resistance in human skeletal muscle","volume":"11","author":"Krebs","year":"2004","journal-title":"Curr Med Chem"},{"key":"10.4158\/EP09155.RA_bb0200","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI0215001","article-title":"Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy","volume":"109","author":"Petersen","year":"2002","journal-title":"J Clin Invest"},{"key":"10.4158\/EP09155.RA_bb0205","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1172\/JCI5001","article-title":"Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity","volume":"103","author":"Dresner","year":"1999","journal-title":"J Clin Invest"},{"key":"10.4158\/EP09155.RA_bb0210","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.2337\/diabetes.48.6.1270","article-title":"Free fatty acid-induced insulin resistance is associated with activation of protein kinase C theta and alterations in the insulin signaling cascade","volume":"48","author":"Griffin","year":"1999","journal-title":"Diabetes"},{"key":"10.4158\/EP09155.RA_bb0215","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2337\/diacare.26.1.30","article-title":"Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy","volume":"26","author":"Simha","year":"2003","journal-title":"Diabetes Care"},{"key":"10.4158\/EP09155.RA_bb0220","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/hep.20672","article-title":"Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy","volume":"41","author":"Javor","year":"2005","journal-title":"Hepatology"},{"key":"10.4158\/EP09155.RA_bb0225","unstructured":"Oral EA, Neidert A, Uhley V et al. Leptin improves nonalcoholic steatohepatitis (NASH) scores in patients with NASH and relative leptin deficiency. Abstract presented at: 91st Endocrine Society Annual Meeting; June 10-13, 2009; Washington, DC."},{"key":"10.4158\/EP09155.RA_bb0230","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1210\/jcem.84.10.5999","volume":"84","author":"Ozata","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09155.RA_bb0235","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1210\/jc.2005-1220","article-title":"Leptin replacement therapy modulates circulating lymphocyte subsets and cytokine responsiveness in severe lipodystrophy","volume":"91","author":"Oral","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09155.RA_bb0240","doi-asserted-by":"crossref","first-page":"4531","DOI":"10.1073\/pnas.0308767101","article-title":"Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults","volume":"101","author":"Licinio","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4158\/EP09155.RA_bb0245","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1210\/jcem.87.7.8591","article-title":"Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy","volume":"87","author":"Oral","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09155.RA_bb0250","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.metabol.2004.08.021","article-title":"The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients","volume":"54","author":"Musso","year":"2005","journal-title":"Metabolism"},{"key":"10.4158\/EP09155.RA_bb0255","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa040388","article-title":"Recombinant human leptin in women with hypothalamic amenorrhea","volume":"351","author":"Welt","year":"2004","journal-title":"N Engl J Med"},{"key":"10.4158\/EP09155.RA_bb0260","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1530\/EJE-08-0597","article-title":"r-metHuLeptin improves highly active antiretroviral therapy-induced lipoatrophy and the metabolic syndrome, but not through altering circulating IGF and IGF-binding protein levels: observational and interventional studies in humans","volume":"160","author":"Brennan","year":"2009","journal-title":"Eur J Endocrinol"},{"key":"10.4158\/EP09155.RA_bb0265","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1210\/jc.2002-020792","article-title":"Effect of subcutaneous leptin replacement therapy on bone metabolism in patients with generalized lipodystrophy","volume":"87","author":"Simha","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09155.RA_bb0270","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1210\/jc.2003-032140","article-title":"Proteinuric nephropathy in acquired and congenital generalized lipodystrophy: baseline characteristics and course during recombinant leptin therapy","volume":"89","author":"Javor","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09155.RA_bb0275","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/jama.282.16.1568","article-title":"Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial","volume":"282","author":"Heymsfield","year":"1999","journal-title":"JAMA"},{"key":"10.4158\/EP09155.RA_bb0280","doi-asserted-by":"crossref","first-page":"7257","DOI":"10.1073\/pnas.0706473105","article-title":"Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies","volume":"105","author":"Roth","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4158\/EP09155.RA_bb0285","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.it.2003.10.013","article-title":"Inflammation: the link between insulin resistance, obesity and diabetes","volume":"25","author":"Dandona","year":"2004","journal-title":"Trends Immunol"},{"key":"10.4158\/EP09155.RA_bb0290","first-page":"II2","article-title":"Inflammation as a cardiovascular risk factor","volume":"109","author":"Willerson","year":"2004","journal-title":"Circulation"},{"key":"10.4158\/EP09155.RA_bb0295","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/sj.ijo.0801825","article-title":"Increased leptin concentrations correlate with increased concentrations of inflammatory markers in morbidly obese individuals","volume":"25","author":"van Dielen","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.4158\/EP09155.RA_bb0300","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1210\/jc.2004-1921","article-title":"Recombinant methionyl human leptin administration to achieve high physiologic or pharmacologic leptin levels does not alter circulating inflammatory marker levels in humans with leptin sufficiency or excess","volume":"90","author":"Chan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09155.RA_bb0305","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/sj.ijo.0801952","article-title":"The effect of pegylated recombinant human leptin (PEG-OB) on weight loss and inflammatory status in obese subjects","volume":"26","author":"Hukshorn","year":"2002","journal-title":"Int J Obes Relat Metab Disord"},{"key":"10.4158\/EP09155.RA_bb0310","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1210\/jc.2003-030803","article-title":"Leptin and the proinflammatory state associated with human obesity","volume":"89","author":"Hukshorn","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.4158\/EP09155.RA_bb0315","doi-asserted-by":"crossref","first-page":"233","DOI":"10.33549\/physiolres.930848","article-title":"Adipocytokines and cancer","volume":"55","author":"Housa","year":"2006","journal-title":"Physiol Res"},{"key":"10.4158\/EP09155.RA_bb0320","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/ncpendmet0456","article-title":"Mechanisms of disease: adipokines and breast cancer\u2014endocrine and paracrine mechanisms that connect adiposity and breast cancer","volume":"3","author":"Sch\u00e4ffler","year":"2007","journal-title":"Nat Clin Pract Endocrinol Metab"},{"key":"10.4158\/EP09155.RA_bb0325","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/sj.jhh.1001856","article-title":"Leptin is independently associated with systolic blood pressure, pulse pressure and arterial compliance in hypertensive African women with increased adiposity: the POWIRS study","volume":"19","author":"Schutte","year":"2005","journal-title":"J Hum Hypertens"},{"key":"10.4158\/EP09155.RA_bb0330","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1001\/jama.287.13.1706","article-title":"Effect of leptin on arterial thrombosis following vascular injury in mice","volume":"287","author":"Bodary","year":"2002","journal-title":"JAMA"},{"key":"10.4158\/EP09155.RA_bb0335","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1046\/j.1538-7836.2003.00445.x","article-title":"Leptin increase is associated with markers of the hemostatic system in obese healthy women","volume":"1","author":"Guagnano","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.4158\/EP09155.RA_bb0340","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1053\/jhep.2001.26518","article-title":"Leptin augments inflammatory and profibrogenic responses in the murine liver induced by hepatotoxic chemicals","volume":"34","author":"Ikejima","year":"2001","journal-title":"Hepatology"},{"key":"10.4158\/EP09155.RA_bb0345","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3109\/10428190009148392","article-title":"Leptin receptor and leukemia","volume":"36","author":"Hino","year":"2000","journal-title":"Leuk Lymphoma"},{"key":"10.4158\/EP09155.RA_bb0350","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.2337\/diabetes.53.9.2443","article-title":"Leptin stimulates ischemia-induced retinal neovascularization: possible role of vascular endothelial growth factor expressed in retinal endothelial cells","volume":"53","author":"Suganami","year":"2004","journal-title":"Diabetes"},{"key":"10.4158\/EP09155.RA_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2002.29865","article-title":"Leptin and renal disease","volume":"39","author":"Wolf","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.4158\/EP09155.RA_bb0360","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1111\/j.1365-4632.2006.02888.x","article-title":"Peripheral T-cell lymphoma presenting as lipoatrophy and nodules","volume":"45","author":"Yiannias","year":"2006","journal-title":"Int J Dermatol"},{"key":"10.4158\/EP09155.RA_bb0365","unstructured":"Compassionate use and treatment IND programs. Crit Path AIDS Proj. 1996;Fall(no. 31):40-67."}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20419652?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X20419652?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/aace.metapress.com\/index\/E2N14628X168001N.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:51:01Z","timestamp":1761515461000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X20419652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["S1530891X20419652"],"URL":"https:\/\/doi.org\/10.4158\/ep09155.ra","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale for Leptin-Replacement Therapy for Severe Lipodystrophy","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.4158\/EP09155.RA","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}